Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET
Company Participants
Todd Friedman - Senior Director of Investor Relations
Christian Henry - President and Chief Executive Officer
Susan Kim - Chief Financial Officer
Conference Call Participants
Kyle Mikson - Canaccord Genuity Corp.
Daniel Brennan - TD Cowen
Doug Schenkel - Wolfe Research
Sung Ji Nam - Scotiabank
Tejas Savant - Morgan Stanley
Operator
Hello and welcome to the PacBio First Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] As a reminder this conference is being recorded.
I would now like to hand the call to Todd Friedman, Senior Director of Investor Relations. Please go ahead.
Todd Friedman
Good afternoon, and welcome to PacBio's first quarter 2024 earnings conference call.
Earlier today, we issued a press release outlining the financial results, we will be discussing on today's call, a copy of which is available on the Investors section of our website at www.pacb.com or as furnished on Form 8-K available on the Securities and Exchange Commission website at www.sec.gov. A copy of our earnings presentation is also available on the Investor section of our website at www.pacb.com.
With me today are Christian Henry, President and Chief Executive Officer; and Susan Kim, Chief Financial Officer.
On today's call, we will be making forward-looking statements, including statements regarding predictions, progress, estimates, plans, intentions, guidance, and others, including expectations with respect to our growth potential, instrument and consumable sales, our commitment to create a sustainable cash flow positive company by the end of 2026, expectations with respect to certain customers being early in the ramp-up and measures to increase their utilization. GAAP and non-GAAP guidance and expected benefits of using PacBio products or technologies and new product expectations.
You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause our actual results to differ materially from those projected or discussed.
We refer you to the documents that we filed with the SEC, including our most recent Forms 10-Q and 10-K, and our recent press release to better understand the risks and uncertainties that could cause actual results to differ. We disclaim any obligation to update or revise these forward-looking statements except as required by law.
We will also present certain financial information on a non-GAAP basis. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement in understanding of the Company's operating results as reported under U.S. GAAP.